June 2, 2020 Impact: High During the virtual AAN 2020 conference, Biogen presented the baseline characteristics of participants in its phase 2 SPARK study of cinpanemab in PD. On May 20th, a month after the virtual conference, AAN opened…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-06-02 20:55:512020-06-02 21:01:31Baseline Characteristics of Biogen's Phase 2 study of cinpanemab in PD
May 7, 2020 Impact: Moderate Cortexyme today announced the publication of research further documenting the ability of the pathogen Porphyromonas gingivalis to invade neurons and trigger Alzheimer’s-like neuropathology. This paper was…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-05-07 17:56:482020-05-07 17:56:48Cortexyme Publishes Data on P. Gingivalis Ability to Infect Neurons and Drive Alzheimer’s-Like Pathology
May 7, 2020 Impact: Moderate Supernus Pharmaceuticals announced that it will acquire the CNS portfolio of US WorldMeds, including Apokyn, Myobloc, and Xadago, as well as the phase 3 Apomorphine Infusion Pump, which is expected to be filed…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-05-07 12:50:192020-05-07 12:50:19Supernus to Acquire CNS Portfolio from US WorldMeds
March 24, 2020 Impact: Moderate FDA has announced that it will postpone or cancel all non-essential meetings through April 30, 2020 due to COVID-19. The following meetings are affected: April 21, 2020: FDA Pulmonary-Allergy Drugs…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-03-24 15:26:562020-03-24 15:26:56FDA to Cancel or Postpone Non-Essential Meetings through April 2020
March 20, 2020 Impact: High Regeneron and Sanofi have announced the initiation of a U.S. phase 2/3 trial evaluating anti-IL6 mAb Kevzara (sarilumab) in patients hospitalized with severe COVID-19 infection, to begin at medical centers in…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-03-20 13:50:262020-03-20 13:50:26Phase 2/3 U.S. trial of Kevzara to initiate in COVID-19 patients
February 7, 2020 Impact: Moderate Innovent Biologics and Eli Lilly have announced that the phase 3 ORIENT-11 trial (NCT03607539) in China has met its primary endpoint of progression-free survival (PFS) for the use of Tyvyt (sintilimab)…